An interventional study of Exercise-Based Cardiac Rehabilitation and Guideline-Directed Medical Therapy in HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction and Readmission Rates, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one has the largest planned enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 14th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 60+ · Women only
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 390 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 64 across the 14 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.
3 of the studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06992089Fundación para la Investigación del Hospital Clínico de ValenciaSHort Of Pace - Heart Failure (SHOP-HF) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare utilization. Despite recent advances in pharmacological therapy, many patients continue to experience recurrent clinical deterioration and functional decline. Exercise-based cardiac rehabilitation has demonstrated benefits in improving physical performance and quality of life. Still, its effect on long-term clinical outcomes in patients with high-risk HFpEF has not been established.
The EMPOWER-HFpEF study is a multicenter, randomized, controlled trial designed to evaluate whether an early, individualized, multimodal exercise-based cardiac rehabilitation program improves clinical outcomes compared with usual care in patients with HFpEF. Eligible participants will be randomly assigned in a 1:1 ratio to receive either usual care alone or usual care plus a structured 12-month exercise-based cardiac rehabilitation program. The intervention includes an initial 6-month supervised phase, followed by a 6-month hybrid phase combining supervised sessions with structured home- or community-based exercise to promote long-term adherence and maintenance of physical activity.
The primary objective is to determine whether this rehabilitation strategy reduces adverse clinical outcomes, including all-cause mortality, heart failure hospitalizations, all-cause hospitalizations, and outpatient heart failure decompensation, while improving functional capacity and health-related quality of life over 12 months. The results of this study will provide evidence on the effectiveness of a long-term multimodal exercise-based cardiac rehabilitation program as part of the comprehensive management of patients with HFpEF.
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and is associated with a high burden of recurrent hospitalizations, impaired functional capacity, and reduced health-related quality of life. Despite advances in guideline-directed medical therapy, many patients continue to experience recurrent clinical events and progressive functional decline. Exercise-based cardiac rehabilitation has demonstrated consistent benefits on exercise capacity and quality of life in patients with heart failure; however, robust evidence regarding its impact on long-term clinical outcomes in patients with HFpEF remains limited, particularly in high-risk populations.
EMPOWER-HFpEF is a multicenter, prospective, randomized, controlled clinical trial designed to evaluate the effectiveness of an early, individualized, multimodal exercise-based cardiac rehabilitation program in patients with high-risk HFpEF. Eligible participants will be randomly assigned in a 1:1 ratio to receive either guideline-directed medical therapy alone or guideline-directed medical therapy plus a structured exercise-based cardiac rehabilitation program. The intervention will be delivered over 12 months and consists of an initial 6-month supervised phase, followed by a 6-month hybrid phase that combines supervised and home-based exercise, with the to promote long-term adherence and maintenance of physical activity.
Participants will be followed for 12 months. The study is designed to determine whether this rehabilitation strategy improves clinically relevant outcomes while preserving functional status and health-related quality of life. The results are expected to provide evidence to support the integration of long-term exercise-based cardiac rehabilitation into the routine management of patients with HFpEF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive guideline-directed medical therapy, regular follow-up in the heart failure clinic, lifestyle education, and individualized recommendations for home-based physical activity, in accordance with current clinical practice.
Other: Guideline-Directed Medical Therapy
Participants receive guideline-directed medical therapy plus a structured 12-month exercise-based cardiac rehabilitation program consisting of a 6-month supervised phase followed by a 6-month hybrid supervised and home-based phase.
Behavioral: Exercise-Based Cardiac Rehabilitation · Other: Guideline-Directed Medical Therapy
A structured, individualised, multimodal exercise-based cardiac rehabilitation program delivered over 12 months. The intervention includes aerobic exercise, resistance training, inspiratory muscle training, and lifestyle counselling. It consists of an initial 6-month supervised phase, followed by a 6-month hybrid phase that combines supervised and home-based exercise to promote long-term adherence and maintenance of physical activity.
Participants receive guideline-directed medical therapy according to current heart failure guidelines, regular follow-up in the heart failure clinic, lifestyle education, and individualized recommendations to maintain regular physical activity as part of routine clinical care.
Hierarchical composite clinical outcome (win ratio)
Comparison between treatment groups using a hierarchical composite endpoint analyzed according to the win ratio method. The hierarchical endpoint includes, in order of priority, all-cause mortality, heart failure hospitalization, all-cause hospitalization, outpatient heart failure decompensation without hospitalization, days alive and out of hospital, change in physical function assessed by the Short Physical Performance Battery (SPPB; total score range 0-12, with higher scores indicating better physical function), and change in health-related quality of life assessed by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS; score range 0-100, with higher scores indicating better health status).
Time frame: 12 months
All-Cause Mortality
Occurrence of death from any cause.
Time frame: 12 months
Heart Failure Hospitalization or Outpatient Heart Failure Decompensation
Occurrence of hospitalization for worsening heart failure or outpatient heart failure decompensation not requiring hospitalization.
Time frame: 12 months
All-Cause Hospitalization
Occurrence of hospitalization for any cause.
Time frame: 12 months
Health-Related Quality of Life
Change from baseline in health-related quality of life assessed using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS). Scores range from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline and 12 months
Physical Function
Change from baseline in physical function assessed using the Short Physical Performance Battery (SPPB). The SPPB total score ranges from 0 to 12 points, with higher scores indicating better lower extremity physical performance and functional status.
Time frame: Baseline and 12 months
Peak Oxygen Uptake
Change from baseline in peak oxygen uptake (peak VO₂), measured by symptom-limited cardiopulmonary exercise testing and expressed as mL/kg/min, in a predefined subgroup of approximately 80 participants.
Time frame: Baseline and 12 months
Left Ventricular Diastolic Function
Change from baseline in left ventricular filling pressure, assessed by transthoracic echocardiography using the average E/e' ratio, calculated from septal and lateral mitral annular early diastolic velocities. Unit of Measure: Average E/e' ratio (unitless)
Time frame: Baseline and 12 months
Right Ventricular Systolic Function
Change from baseline in right ventricular systolic function, assessed by transthoracic echocardiography using tricuspid annular plane systolic excursion (TAPSE). Unit of Measure: millimetres (mm)
Time frame: Baseline and 12 months
Left Ventricular End-Diastolic Volume Index
Change from baseline in left ventricular end-diastolic volume index (LVEDVi) measured by transthoracic echocardiography using the biplane Simpson method and indexed to body surface area. Unit of Measure: millilitres per square meter (mL/m²)
Time frame: Baseline and 12 months
Estimated Pulmonary Artery Systolic Pressure
Change from baseline in estimated pulmonary artery systolic pressure (PASP) assessed by transthoracic echocardiography using the peak tricuspid regurgitation velocity and estimated right atrial pressure. Unit of Measure: millimetres of mercury (mmHg)
Time frame: Baseline and 12 months
Heart Failure Biomarker: N-terminal Pro-B-type Natriuretic Peptide
Change from baseline in circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration. Unit of Measure: pg/mL
Time frame: Baseline and 12 months
Heart Failure Biomarker: Carbohydrate Antigen 125
Change from baseline in circulating carbohydrate antigen 125 (CA125) concentration. Unit of Measure: U/mL
Time frame: Baseline and 12 months
Plan to share: Yes — De-identified individual participant data relevant to the published study findings will be considered for sharing following an appropriate request, subject to applicable institutional policies and ethical and legal requirements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: De-identified individual participant data and supporting documents will be considered for sharing following publication of the primary study results, for a period to be determined in accordance with institutional policies and applicable regulations.
Access criteria: Access to de-identified individual participant data and supporting documentation will be considered upon reasonable request. Requests will be reviewed on a case-by-case basis by the study investigators in accordance with institutional policies, ethical requirements, and applicable legal and regulatory frameworks. Access may require a data sharing agreement
Data sharing details ↗ · www.incliva.es
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2031, 60 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 60 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación del Hospital Clínico de Valencia